SN
SNANF.US Sona Nanotech Inc
- Market cap
- USD 24.2M
- P/E
- -
- P/B
- 64.97x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jul 2026.
Is SNANF.US undervalued?
Graham numberThe Graham number of Sona Nanotech Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sona Nanotech Inc fundamental analysis
No fundamental analysis for Sona Nanotech Inc yet.
Sona Nanotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sona Nanotech Inc
Sona Nanotech Inc. operates as a nanotechnology life sciences company in the United States and Canada The company researchers and develops gold nanoparticles for potential therapies, including photothermal therapy, tumor targeting activity, anti-bacterial activity, and drug delivery vehicle, as well as diagnostics, such as diagnostic markers for imaging and immunoassay and biosensing. It also engages in the development of targeted hyperthermia therapy, a photo thermal therap…
Full company profileSona Nanotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sona Nanotech Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -592K | -358K | -5.18M | -1.66M | -9.13M | -10.7M | -3.14M | -2.65M | -2.92M | -3.44M | -2.47M |
| EBITDA | - | -2.24M | -5.09M | -2.32M | -6.18M | -10.3M | -2.22M | -1.97M | -1.92M | -2.49M | -1.75M |
| Net Income | -643K | -2.28M | -5.20M | -2.52M | -6.27M | -10.4M | -2.36M | -2.50M | -2.70M | -3.25M | -2.51M |
| EPS | - | -0.03 | -0.10 | -0.04 | -0.10 | -0.16 | -0.03 | -0.03 | -0.02 | -0.03 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 4.85M | 1.74M | 3.18M | 859K | 725K | 1.52M | 521K | 2.75M | 3.75M | 1.33M | 543K |
| Total Liabilities | 2.17M | 1.71M | 2.98M | 1.88M | 4.16M | 2.75M | 1.03M | 1.59M | 1.24M | 1.37M | 1.81M |
| Shareholders' Equity | 2.68M | 24.5K | 199K | -1.02M | -3.44M | -1.22M | -508K | 1.16M | 2.51M | -38.8K | -1.26M |
| Cash & Short-term Investments | 0.00 | 429K | 1.80M | 581K | 103K | 1.18M | 155K | 109K | 1.85M | 122K | 14.2K |
| Total Debt | 87.7K | - | - | - | - | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -328K | -244K | -1.55M | -1.36M | -4.05M | -3.81M | -1.81M | -1.26M | -1.96M | -1.96M | -739K |
| Capital Expenditure | 651.00 | 23.5K | 146K | 159K | 377K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -176K | -1.54M | -1.52M | -4.75M | -3.81M | -1.81M | -1.26M | -1.96M | -1.96M | -739K |
| Ratios | |||||||||||
| ROE | -24.0% | -9,312.9% | -2,610.3% | - | - | - | - | -215.1% | -107.8% | - | - |
| ROA | -13.2% | -131.5% | -163.5% | -293.4% | -865.5% | -680.6% | -453.4% | -91.0% | -72.2% | -244.5% | -463.2% |
| Debt to Equity | 0.03x | - | - | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sona Nanotech Inc dividends
Sona Nanotech Inc has not paid dividends in the last 9 fiscal years.
Who owns Sona Nanotech Inc
- Insiders 17.63%
- Institutions 0.00%
- Public & others 82.37%
- Shares outstanding 123M
- Free float 105M
Sona Nanotech Inc company profile
- Company name
- Sona Nanotech Inc
- Ticker
- SNANF.US
- ISIN
- CA83541C1059
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- October
- Address
- Purdy?s Wharf Tower II, Halifax, NS, Canada, B3J 3R7
- Phone
- 902 442 0653
- Website
- sonanano.com
About Sona Nanotech Inc
Sona Nanotech Inc. operates as a nanotechnology life sciences company in the United States and Canada The company researchers and develops gold nanoparticles for potential therapies, including photothermal therapy, tumor targeting activity, anti-bacterial activity, and drug delivery vehicle, as well as diagnostics, such as diagnostic markers for imaging and immunoassay and biosensing. It also engages in the development of targeted hyperthermia therapy, a photo thermal therapy for the treatment of cancer tumors; and diagnostic tools comprising lateral flow assay rapid and bovine tuberculosis tests. The company was founded in 2013 and is based in Halifax, Canada.
Sona Nanotech Inc management
6- Mr. David Andrew ReganChief Executive Officer · born 1969
- Mr. Robert William George Randall CPACFO & Corporate Secretary · born 1963
- Dr. Carman Giacomantonio M.D., M.Sc.Chief Medical Officer
- Dr. Kulbir Singh Ph.D.Co-Founder, Head of R&D & Chief Technology Officer
- Dr. Mike McAlduffDirector of R&D & Production and Founder
- Dr. Gerrard MarangoniCo-Founder & Member of Scientific Advisory Board